As Merck continues its post-Vioxx makeover, the company is prowling for a nice biotech company to buy.
Merck CEO Richard Clark told Dow Jones Newswires’ Peter Loftus that the “perfect” deal would be a company with a mid-sized market cap, some products already for sale and a research focus that would complement Merck’s research efforts. “We’re [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment